SBIR/STTR Research Award

Near Infrared Semiconductor Nanocrystal for Imaging Guided Surgery

Award identifier 3f01c8e7babd61d42392bb8ee66b259b4f9858195c5ae91ad61d2bd8116e3b91Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$170,679

Program and phase

SBIR · Phase I

Award year

2009

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
NANOMATERIALS AND NANOFABRICATION LABORATORIES
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2009-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Nanomaterials and Nanofabrication Laboratories Program Announcement No. PA-08-050 (NN-Labs, LLC) Title: Near Infrared Semiconductor Nanocrystal for Imaging Guided Surgery Principal Investigator: Tiecheng Qiao Summary The incidence of brain metastasis in patients with melanoma ranges from 10% to 40% and is even higher in autopsy series. Survival rate for patients with stage IV disease is typically measured in months. Surgery is usually recommended for single brain metastases in patients with controlled or controllable systemic disease. A complete and aggressive surgical resection should be performed whenever possible followed by post-operative radiation. However, the ability to achieve complete resection (i.e., negative margin) is sometimes limited by the surgeon's ability to distinguish residual tumor from surrounding brain tissue under conventional white-light illumination. To address this technical difficulty, this Phase I project will develop a novel class of near infrared nanoparticles (NIR-NP) for imaging guide surgery (ICG) applications. Such materials are not commercially available today and will provide surgeons an ease of use surgical navigation imaging agent with precision and real time feedback, and overall, improve clinical outcome for cancer patients. We will select a tumor targeting peptide that will be attached to the surface of NIR nanoparticles. Tumor bearing mice will be used as a model to show the preferably accumulation of NIR nanoparticles on tumor site. The advantage of using a NIR nanoparticles guided resection of tumor in mice versus simple visual resection will be demonstrated. Criteria for success involve the following requirements: 1. The NIR nanoparticles must be readily dispersible biological benign solution, such as phosphate buffer saline solution (PBS), without agglomeration, 2. The NIR nanoparticles must possess good biodistribution and body clearance profile, 3. The NIR nanoparticle must meet, or exceed, clinical requirements. We will evaluate the cytotoxicity and biocompatibility of our NIR-NP through a series of in vitro assays. Ultimately, we will demonstrate the feasibility and benefit of using NIR-NP in IGS over conventional visual surgery in mice model with subcutaneously inoculated B16-BL6 melanoma. 1 PUBLIC HEALTH RELEVANCE: Approximately 1.5 million people in the US are diagnosed with cancer annually; and half of the 1.5 million new cancer cases diagnosed in the U.S. this year will be treated with excision surgery. One common problem associated with tumor-related surgical procedures is the difficulty for surgeons to visualize the tumor margin before the operation and to complete the excision of cancerous tissue during surgery. It is estimated that tumor reoccurrence rate could be as high as 20-30% after tumor-excision surgical procedures, and that the subsequent metastasis of unexcised cancerous growth leads to further clinical complications. The goal of this program is to develop an imaging guided surgery system using near infrared nanoparticles that would allow surgeons to maximizing tumor removal with minimal peri-tumoral damage to surrounding normal tissue. Near infrared imaging has the potential to improve the intraoperative detection of patients with malignant tumor that surgical resection is a must procedure. It is anticipated that the reduced costs and higher resolutions will permit more complete tumor resections, more accurate biopsies, and faster procedures with better patient outcomes and lower patient cost and morbidity.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.